{'fraction_non_alphanumeric': 0.045004500450045004, 'fraction_numerical': 0.017101710171017102, 'mean_word_length': 5.143646408839779, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Immunopharmacological studies of PTT.119, a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative.

The new synthetic tripeptide p-F-Phe-m-bis-(2-chloro-ethyl)amino-Phe-Met-etoxy HCl, PTT.119, was studied for its effects on the host immune system. Doses of PTT.119 ranging from 3 to 18 mg/kg were administered i.p. to recipient mice which, at different times after drug treatment, were tested for allograft response, competence in producing lymphocytes active in lethal graft-versus-host disease, delayed-type hypersensitivity, mitogen responsiveness, humoral antibody production and natural resistance against microbial infections. At therapeutically active dosages, PTT.119 appeared to selectively inhibit functions mediated by B lymphocytes, leaving the majority of those involving T-cell subsets largely unaffected, even at the highest doses employed. Moreover, drug treatment had also a limited impact on the in vivo resistance of mice to microbial infection, which was only affected by a drug injection of 18 mg/kg, a dose well within the confidence limits of the mean lethal dose of the drug.